Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel A Pollyea

Showing results (61-70 of 179) with videos related to

Pageof 18
Sort By:
Bone Marrow Transplantation|May 15, 2023
Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapseAndrew Kent, Marc Schwartz, Christine McMahon, et al.
Leukemia & Lymphoma|December 30, 2020
The propriety of upgrading responses to venetoclax + azacitidine in newly diagnosed patients with acute myeloid leukemiaDiana Abbott, Evan Cherry, Maria Amaya, et al.
American Journal of Hematology|June 4, 2014
Inhibition of calcineurin combined with dasatinib has direct and indirect anti-leukemia effects against BCR-ABL1(+) leukemiaLori A Gardner, Jelena Klawitter, Mark A Gregory, et al.
American Journal of Hematology|August 14, 2025
Known Prognostic Models Fail to Predict Outcomes for Venetoclax and Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia: A Single-Center Retrospective AnalysisJason S Gilbert, Megan Connor, Grace Bosma, et al.
Annals of Hematology|February 2, 2023
Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United StatesAmer M Zeidan, Daniel A Pollyea, Uma Borate, et al.
Annals of Hematology|June 21, 2023
Correction to: Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United StatesAmer M Zeidan, Daniel A Pollyea, Uma Borate, et al.
Leukemia Research|June 1, 2023
Outcomes with molecularly targeted agents as salvage therapy following frontline venetoclax + hypomethylating agent in adults with acute myeloid leukemia: A multicenter retrospective analysisVishesh Khanna, Tali Azenkot, Selina Qiuying Liu, et al.
American Journal of Hematology|January 9, 2026
Long-Term Outcomes of Stem Cell Transplant in Older Patients With Acute Myeloid Leukemia Treated With Venetoclax-Based TherapiesKeith W Pratz, Courtney D DiNardo, Martha Arellano, et al.
Blood|May 19, 2019
Cysteine depletion targets leukemia stem cells through inhibition of electron transport complex IICourtney L Jones, Brett M Stevens, Angelo D'Alessandro, et al.
American Journal of Hematology|September 28, 2010
Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: a single-center experienceHolbrook E Kohrt, Samit Patel, Michelle Ho, et al.
Pageof 18

Showing results (61-70 of 179) with videos related to

Sort By:
Pageof 18
Bone Marrow Transplantation|May 15, 2023
Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapseAndrew Kent, Marc Schwartz, Christine McMahon, et al.
Leukemia & Lymphoma|December 30, 2020
The propriety of upgrading responses to venetoclax + azacitidine in newly diagnosed patients with acute myeloid leukemiaDiana Abbott, Evan Cherry, Maria Amaya, et al.
American Journal of Hematology|June 4, 2014
Inhibition of calcineurin combined with dasatinib has direct and indirect anti-leukemia effects against BCR-ABL1(+) leukemiaLori A Gardner, Jelena Klawitter, Mark A Gregory, et al.
American Journal of Hematology|August 14, 2025
Known Prognostic Models Fail to Predict Outcomes for Venetoclax and Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia: A Single-Center Retrospective AnalysisJason S Gilbert, Megan Connor, Grace Bosma, et al.
Annals of Hematology|February 2, 2023
Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United StatesAmer M Zeidan, Daniel A Pollyea, Uma Borate, et al.
Annals of Hematology|June 21, 2023
Correction to: Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United StatesAmer M Zeidan, Daniel A Pollyea, Uma Borate, et al.
Leukemia Research|June 1, 2023
Outcomes with molecularly targeted agents as salvage therapy following frontline venetoclax + hypomethylating agent in adults with acute myeloid leukemia: A multicenter retrospective analysisVishesh Khanna, Tali Azenkot, Selina Qiuying Liu, et al.
American Journal of Hematology|January 9, 2026
Long-Term Outcomes of Stem Cell Transplant in Older Patients With Acute Myeloid Leukemia Treated With Venetoclax-Based TherapiesKeith W Pratz, Courtney D DiNardo, Martha Arellano, et al.
Blood|May 19, 2019
Cysteine depletion targets leukemia stem cells through inhibition of electron transport complex IICourtney L Jones, Brett M Stevens, Angelo D'Alessandro, et al.
American Journal of Hematology|September 28, 2010
Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: a single-center experienceHolbrook E Kohrt, Samit Patel, Michelle Ho, et al.
Pageof 18